Prospects for "EuroNICE" and a single European pharma pricing market

Despite a current void, increasing ties between pricing and reimbursement authorities across Europe through reference pricing and cost-effectiveness show a clear momentum towards regulatory harmonization. Global Insight examines the scope and potential for a single European pricing market.

- There are already significant processes and institutions in place to create a single European pricing and reimbursement (P&R) market. The European Commission, alongside the European Union price transparency directive and information-sharing for cost-effectiveness, is the primary source for potential institution-building.

- The vast network of parallel trading and international reference pricing ensures that Europe is already a significantly harmonised market, although each country has a deeply engrained national health care system.